Susceptibility to fluconazole and voriconazole of Candida species isolated from intensive care units patients in Medellin, Colombia (2001-2007);Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001-2007)

Revista Iberoamericana de Micologia

Volumn 27, Issue 3, 2010, Pages 125-129

  Zuluaga Rodríguez, Alejandra ^a   de Bedout Gómez, Catalina ^a   Agudelo Restrepo, Carlos Andrés ^a,b   Hurtado Parra, Hans ^a   Arango Arteaga, Myrtha ^a,c   Restrepo Moreno, Ángela ^a   González Marín, Ángel ^a,c  

^a Unidad de Biología Celular y Molecular   (Colombia)

^b UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Antif ngicos; Candida spp.; Fluconazol; Prueba de disco; Resistencia; Sensibilidad; Voriconazol

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; COLOMBIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGUS ISOLATION; INTENSIVE CARE; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; YARROWIA LIPOLYTICA;

ANTIFUNGAL AGENTS; CANDIDA; COLOMBIA; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; DEBARYOMYCES HANSENII; ISSATCHENKIA ORIENTALIS; PICHIA ANOMALA; PICHIA GUILLIERMONDII; YARROWIA LIPOLYTICA;

EID: 77956876778     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.riam.2010.04.001     Document Type: Article

References (22)

1. Abi-said D., Anaissie E., Uzun O., Raad I., Pincowski H., Varvitarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128.
2. Alexander B.A., Pfaller M. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006, 43:S15-S27.
3. Bassetti M., Righi E., Costa A., Fasce R., Molinari M.P., Rosso R., et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006, 6:21.
4. Boucher H.W., Groll A.H., Chiou C.C., Walsh T.J. Newer systemic antifungal agents-pharmacokinetics, safety and efficacy. Drugs 2004, 64:1997-2020.
5. Colombo A., Nucci M., Park B.J., Nouer S.A., Arthington-Skaggs B., Damatta D.A., et al. Epidemiology of candidemia in Brasil: A nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44:2816-2823.
6. Chakrabarti A., Chatterjee S.S., Rao K.L., Zameer M.M., Shivaprakash M.R., Singhi S., et al. Recent experience with fungaemia: Change in species distribution and azole resistance. Scand J Infect Dis 2009, 41:275-284.
7. Diomedi A. Nuevos antifúngicos: Las equinocandinas. Rev Chil Infect 2004, 21:89-101.
8. Eggimann P., Garbino J., Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685-702.
9. Fridkin S.K. The changing face of fungal infections in health care setting. Clin Infect Dis 2005, 41:1455-1460.
10. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia. Clin Infect Dis 2003, 37:1172-1177.
11. Lee J.K., Peters D., Obias A.A., Noskin G.A., Peterson L.R. Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984. Int J Antimicrob Agents 2000, 16:205-209.
12. Leroy O., Gangneux J.P., Montravers P., Mira J.P., Gouin F., Sollet J.P., et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618. AmarCand Study Group.
13. Mujica M.T., Finquelievich J.L., Jewtuchowicz C.A., Iovannitti C.A. Prevalencia de Candida albicans y Candida no albicans en diferentes muestras clínicas. Período 1999-2001. Rev Arg Microbiol 2004, 36:107-112.
14. National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeast. Approved guideline M44-A. National Committee for Clinical Laboratory Standards, Wayne, Pa 19087-1998. 2004;24:1-23.
15. Pappas P., Kauffman C., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
16. Pfaller M.A., Pappas P.G., Wingard J.R. Invasive fungal phatogens: Current epidemiological trends. Clin Infect Dis 2006, 43:S3-S14.
17. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., et al. Correlation of MIC with outcome for Candida species tested against voriconazol: Analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006, 44:819-826.
18. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
19. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ng K.P., Colombo A., et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: A global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008, 43:842-849. and The Global Antifungal Surveillance Group.
20. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Nagy E., Dibiasova S., et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: Geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2008, 46:515-521.
21. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2:73-85.
22. St-Germain G., Laverdière M., Pelletier R., Bourgault A.M., Libman M., Lemieux C., et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canadá. J Clin Microbiol 2001, 39:949-953.